Soft tissue sarcoma — a rare tumor — affecting less than 1% of the population — has the major unmet need in the form of limited treatment options for patients.
Cytotoxic chemotherapy has been the mainstay of #therapy for decades.
Pharma companies including Blueprint Medicines, Advenchen Laboratories, LLC / Jiangsu Chia-Tai Tianqing Pharmaceutical, Karyopharm Therapeutics Inc., Deciphera Pharmaceuticals, Philogen SpA, GSK, Epizyme, Eli Lilly and Company, and several others are advancing the Soft Tissue Sarcoma Treatment market with novel therapies under trials in their pipeline, soon to be launched in the coming decade.
To read more visit: https://www.delveinsight.com/blog/soft-tissue-sarcoma-treatment-market/